Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 391-399

  Yablecovitch, Doron ^a,b,c   Shabat Simon, Maytal ^a   Aharoni, Rina ^a   Eilam, Raya ^a   Brenner, Ori ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; GLATIRAMER; SYNDECAN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DESCENDING COLON; EPITHELIUM CELL; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; STAINING; TISSUE REPAIR;

ACUTE DISEASE; ADOPTIVE TRANSFER; ANIMALS; ANTI-INFLAMMATORY AGENTS; CECUM; CHRONIC DISEASE; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; SYNDECAN-1;

EID: 79955043804     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174276     Document Type: Article

References (37)

1. Aharoni R, Kayhan B, and Arnon R (2005) Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis 11:106-115. (Pubitemid 40711214)
2. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, and Arnon R (2006) Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 318:68-78.
3. Aharoni R, Sonego H, Brenner O, Eilam R, and Arnon R (2007) The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 112:110-119. (Pubitemid 47379855)
4. Aharoni R, Teitelbaum D, Sela M, and Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94:10821-10826. (Pubitemid 27430819)
5. Arnon R and SelaM(2003) Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 16:412-421. (Pubitemid 38161969)
6. Bartlett AH, Hayashida K, and Park PW (2007) Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells 24:153-166. (Pubitemid 350177174)
7. Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S, and Freeze HH (2008) Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 118: 229-238.
8. Carey DJ (1997) Syndecans: Multifunctional cell-surface co-receptors. Biochem J 327 (Pt 1):1-16. (Pubitemid 27455453)
9. Cooper HS, Murthy SN, Shah RS, and Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-249.
10. Day R and Forbes A (1999) Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354:62-65. (Pubitemid 29304311)
11. Day R, Ilyas M, Daszak P, Talbot I, and Forbes A (1999) Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 44:2508-2515. (Pubitemid 30027369)
12. Day RM, Mitchell TJ, Knight SC, and Forbes A (2003) Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine 21:224-233. (Pubitemid 36765414)
13. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pen AS, Meuwissen SG, and Van Rees EP (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391. (Pubitemid 28539597)
14. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, and Elson CO (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643-1652. (Pubitemid 24357616)
15. Fiocchi C (1998) Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 115:182-205. (Pubitemid 28307304)
16. Ford HR (2006) Mechanism of nitric oxide-mediated intestinal barrier failure: Insight into the pathogenesis of necrotizing enterocolitis. J Pediatr Surg 41:294-299. (Pubitemid 43233841)
17. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T, Arnon R, and Sela M (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cellsspecificity and promiscuity. Proc Natl Acad Sci USA 91:4872-4876.
18. Gaffney PR, O'Leary JJ, Doyle CT, Gaffney A, Hogan J, Smew F, and Annis P (1991) Response to heparin in patients with ulcerative colitis. Lancet 337:238-239.
19. Götte M (2003) Syndecans in inflammation. FASEB J 17:575-591. (Pubitemid 37221142)
20. Hashimoto Y, Skacel M, and Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors. BMC Cancer 8:185.
21. Hayashida K, Johnston DR, Goldberger O, and Park PW (2006) Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem 281:24365-24374. (Pubitemid 44274208)
22. Henry-Stanley MJ, Zhang B, Erlandsen SL, and Wells CL (2006) Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on enterocyte shedding of syndecan-1 and associated decreases in internalization of Listeria monocytogenes and Staphylococcus aureus. Cytokine 34:252-259. (Pubitemid 44224106)
23. Hirabayashi K, Numa F, Suminami Y, Murakami A, Murakami T, and Kato H (1998) Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumour Biol 19:454-463. (Pubitemid 28539327)
24. Inki P, Joensuu H, Grénman R, Klemi P, and Jalkanen M (1994) Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70:319-323. (Pubitemid 24247157)
25. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, and Van Marck E (1998) Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300-305. (Pubitemid 28494359)
26. Leivonen M, Lundin J, Nordling S, von Boguslawski K, and Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67:11-18. (Pubitemid 39370345)
27. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, and Kohgo Y (1997) Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74:482-491. (Pubitemid 27486504)
28. Melgar S, Karlsson A, and Michaëlsson E (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288:G1328-G1338. (Pubitemid 40741088)
29. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702. (Pubitemid 20069706)
30. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429. (Pubitemid 34851835)
31. Principi M, Day R, Marangi S, Burattini O, De Francesco V, Ingrosso M, Pisani A, Panella C, Forbes A, Di Leo A, et al. (2006) Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol Immunotoxicol 28:185-195. (Pubitemid 44180237)
32. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, and Grénman R (1997) Syndecan-1: A new prognostic marker in laryngeal cancer. Acta Otolaryngol 117:312-315. (Pubitemid 27151781)
33. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, and Borset M (2000) Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 95:388-392. (Pubitemid 30041645)
34. Shanahan F (2001) Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622-635. (Pubitemid 32171636)
35. Wang X, Song YG, He YJ, Lin YZ, Wang XF, and Chen Y (2008) [Syndecan-1 expression and its significance in colitis]. Zhonghua Yi Xue Za Zhi 88:2574-2577.
36. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13:935-943. (Pubitemid 47222047)
37. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, and Haglund C (2001) Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95:1-6.